Intellia Therapeutics Inc
NASDAQ:NTLA

Watchlist Manager
Intellia Therapeutics Inc Logo
Intellia Therapeutics Inc
NASDAQ:NTLA
Watchlist
Price: 14.3 USD 3.62% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Intellia Therapeutics Inc?
Write Note

Intrinsic Value

NTLA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one NTLA stock under the Base Case scenario is 7.61 USD. Compared to the current market price of 14.3 USD, Intellia Therapeutics Inc is Overvalued by 47%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NTLA Intrinsic Value
7.61 USD
Overvaluation 47%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Intellia Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for NTLA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about NTLA?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Intellia Therapeutics Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Intellia Therapeutics Inc

Provide an overview of the primary business activities
of Intellia Therapeutics Inc.

What unique competitive advantages
does Intellia Therapeutics Inc hold over its rivals?

What risks and challenges
does Intellia Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Intellia Therapeutics Inc recently?

Summarize the latest earnings call
of Intellia Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Intellia Therapeutics Inc.

Provide P/S
for Intellia Therapeutics Inc.

Provide P/E
for Intellia Therapeutics Inc.

Provide P/OCF
for Intellia Therapeutics Inc.

Provide P/FCFE
for Intellia Therapeutics Inc.

Provide P/B
for Intellia Therapeutics Inc.

Provide EV/S
for Intellia Therapeutics Inc.

Provide EV/GP
for Intellia Therapeutics Inc.

Provide EV/EBITDA
for Intellia Therapeutics Inc.

Provide EV/EBIT
for Intellia Therapeutics Inc.

Provide EV/OCF
for Intellia Therapeutics Inc.

Provide EV/FCFF
for Intellia Therapeutics Inc.

Provide EV/IC
for Intellia Therapeutics Inc.

Show me price targets
for Intellia Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Intellia Therapeutics Inc?

How accurate were the past Revenue estimates
for Intellia Therapeutics Inc?

What are the Net Income projections
for Intellia Therapeutics Inc?

How accurate were the past Net Income estimates
for Intellia Therapeutics Inc?

What are the EPS projections
for Intellia Therapeutics Inc?

How accurate were the past EPS estimates
for Intellia Therapeutics Inc?

What are the EBIT projections
for Intellia Therapeutics Inc?

How accurate were the past EBIT estimates
for Intellia Therapeutics Inc?

Compare the revenue forecasts
for Intellia Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Intellia Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Intellia Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Intellia Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Intellia Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Intellia Therapeutics Inc with its peers.

Analyze the financial leverage
of Intellia Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Intellia Therapeutics Inc.

Provide ROE
for Intellia Therapeutics Inc.

Provide ROA
for Intellia Therapeutics Inc.

Provide ROIC
for Intellia Therapeutics Inc.

Provide ROCE
for Intellia Therapeutics Inc.

Provide Gross Margin
for Intellia Therapeutics Inc.

Provide Operating Margin
for Intellia Therapeutics Inc.

Provide Net Margin
for Intellia Therapeutics Inc.

Provide FCF Margin
for Intellia Therapeutics Inc.

Show all solvency ratios
for Intellia Therapeutics Inc.

Provide D/E Ratio
for Intellia Therapeutics Inc.

Provide D/A Ratio
for Intellia Therapeutics Inc.

Provide Interest Coverage Ratio
for Intellia Therapeutics Inc.

Provide Altman Z-Score Ratio
for Intellia Therapeutics Inc.

Provide Quick Ratio
for Intellia Therapeutics Inc.

Provide Current Ratio
for Intellia Therapeutics Inc.

Provide Cash Ratio
for Intellia Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Intellia Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Intellia Therapeutics Inc?

What is the current Free Cash Flow
of Intellia Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Intellia Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Intellia Therapeutics Inc

Current Assets 757.2m
Cash & Short-Term Investments 691.1m
Receivables 12.3m
Other Current Assets 53.8m
Non-Current Assets 434.3m
Long-Term Investments 248.8m
PP&E 135.7m
Other Non-Current Assets 49.8m
Current Liabilities 105.1m
Accounts Payable 18.8m
Accrued Liabilities 64.1m
Other Current Liabilities 22.2m
Non-Current Liabilities 115.4m
Other Non-Current Liabilities 115.4m
Efficiency

Earnings Waterfall
Intellia Therapeutics Inc

Revenue
81.3m USD
Operating Expenses
-994.4m USD
Operating Income
-913.1m USD
Other Expenses
41.8m USD
Net Income
-871.3m USD

Free Cash Flow Analysis
Intellia Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

NTLA Profitability Score
Profitability Due Diligence

Intellia Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
Declining ROE
23/100
Profitability
Score

Intellia Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

NTLA Solvency Score
Solvency Due Diligence

Intellia Therapeutics Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
63/100
Solvency
Score

Intellia Therapeutics Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NTLA Price Targets Summary
Intellia Therapeutics Inc

Wall Street analysts forecast NTLA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NTLA is 60.18 USD with a low forecast of 14.14 USD and a high forecast of 134.4 USD.

Lowest
Price Target
14.14 USD
1% Downside
Average
Price Target
60.18 USD
321% Upside
Highest
Price Target
134.4 USD
840% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for NTLA?

Click here to dive deeper.

Dividends

Intellia Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for NTLA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

NTLA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

NTLA News

Other Videos

Profile

Intellia Therapeutics Inc Logo
Intellia Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.4B USD

Dividend Yield

0%

Description

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. The company is headquartered in Cambridge, Massachusetts and currently employs 485 full-time employees. The company went IPO on 2016-05-06. The firm is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). The company is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). The firm is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned T cell receptor (TCR)-T cell candidate, NTLA-5001 for the treatment of acute myeloid leukemia (AML) and hematopoietic stem cells (HSCs) for the treatment of sickle cell disease.

Contact

MASSACHUSETTS
Cambridge
40 Erie St Ste 130
+18572856200.0
www.intelliatx.com

IPO

2016-05-06

Employees

485

Officers

President, CEO & Director
Dr. John M. Leonard M.D.
Executive VP & Chief Scientific Officer
Dr. Laura Sepp-Lorenzino Ph.D.
Executive VP, General Counsel & Corporate Secretary
Mr. James E. Basta Esq., J.D.
Executive VP & Chief Medical Officer
Dr. David Lebwohl M.D.
Co-Founder
Dr. Rachel E. Haurwitz Ph.D.
Founder and Member of Scientific Advisor Board
Dr. Andrew May Ph.D.
Show More
Founder & Member of Scientific Advisor Board
Dr. Rodolphe Barrangou M.B.A., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one NTLA stock?

The intrinsic value of one NTLA stock under the Base Case scenario is 7.61 USD.

Is NTLA stock undervalued or overvalued?

Compared to the current market price of 14.3 USD, Intellia Therapeutics Inc is Overvalued by 47%.

Back to Top